Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur.
Rios-Buceta
L
L
Buezo
G F
GF
Peñas
P F
PF
Dauden
E
E
Fernandez-Herrera
J
J
Garcia-Diez
A
A
D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D004890:Erythema / Q000139:chemically induced*; D005260:Female; D005533:Foot Dermatoses / Q000139:chemically induced*; D006229:Hand Dermatoses / Q000139:chemically induced*; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced*; D007645:Keratoderma, Palmoplantar / Q000209:etiology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D009260:Nail Diseases / Q000139:chemically induced*; D010292:Paresthesia / Q000139:chemically induced*; D013274:Stomach Neoplasms / Q000473:pathology; D005641:Tegafur / Q000009:adverse effects*; D014060:Tongue Diseases / Q000139:chemically induced*
D000964:Antimetabolites, Antineoplastic; D005641:Tegafur